Uncategorized

July 25, 2018

What is The Optimal Duration of Adjuvant Hormone Therapy for Early Stage Breast Cancer?

By

Currently it is recommended that most postmenopausal women with hormone receptor–positive early stage breast cancer be treated with 5 additional years of aromatase inhibitor (AI) therapy following completion of an initial 5 years of treatment. The optimal duration of endocrine (hormone) therapy beyond five years after initial AI adjuvant therapy for postmenopausal women with hormone […]

View full entry


July 23, 2018

Tibsovo Approved for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and an IGH1 Mutation

By

Tibsovo® (ivosidenib) has been granted approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA approved test. Data leading to the FDA approval was from a trial that included […]

View full entry

Tags: Acute Myeloid Leukemia, IGH1 Mutation, Leukemia, News, refractory, relapsed, Tibsovo, treatment


July 23, 2018

FDA Approves Kisqali as Initial Endocrine Therapy for Advanced Breast Cancer

By

The U.S. Food and Drug Administration today approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy. The FDA also approved Kisqali in combination with fulvestrant for the […]

View full entry

Tags: Breast Cancer, News


July 19, 2018

Nimotuzumab in Combination With Concurrent Radiotherapy and Cisplatin Is Active in Locally Advanced SCCHN

By

Nimotuzumab in combination with concurrent radiotherapy and cisplatin provides significant clinical benefits in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). About Head and Neck Cancer Head and neck cancers include a number of different malignant cancers that develop in or around the throat, larynx (voice box), nose, sinuses and […]

View full entry

Tags: EGFR, Head and Neck Cancer, News, Nimotuzumab, treatment


July 17, 2018

FDA Approves Xtandi for Treatment of Castration-resistant Prostate Cancer

By

On July 13, 2018, the Food and Drug Administration approved Xtandi (enzalutamide) for patients with castration-resistant prostate cancer (CRPC).  This approval broadens the indicated patient population to include patients with both non-metastatic CRPC (NM-CRPC) and metastatic CRPC. Xtandi was previously approved for the treatment of patients with metastatic CRPC. About Prostate Cancer Prostate cancer is […]

View full entry

Tags: News, Prostate Cancer


July 12, 2018

Cyramza Improves Survival in Poor-Prognosis Liver Cancer

By

Andrew X. Zhu, MD, PhD, director of Liver Cancer Research at Massachusetts General Hospital presented new data at the 2018 World Congress on Gastrointestinal Cancer (WCGC) demonstrating that Cyramza (ramucirumab) significantly improves survival in a subset of patients with hepatocellular carcinoma (HCC) who have high levels of the plasma protein α-fetoprotein (AFP), which is associated […]

View full entry

Tags: cyramza, hepatocellular cancer treatment, Liver Cancer, News


July 10, 2018

Overall Health, Not Just Age, is an Important Factor in Treatment of Non-Small Cell Lung Cancer

By

Two clinical studies highlight the importance of evaluating overall health instead of age in the management of lung cancer. In fact, younger patients with non-small cell lung cancer (NSCLC) are more likely to receive treatment than older patients, regardless of overall health and prognosis according to the results of a study published in the Journal of […]

View full entry

Tags: Lung Cancer, Lung Cancer - Non-Small Cell, News


July 9, 2018

Aromasin plus Ovarian Suppression Yields Benefit in High-risk Premenopausal Breast Cancer Patients

By

Premenopausal women with hormone receptor-positive, HER2-negative breast cancer and a high risk of recurrence who are treated with an aromatase inhibitor plus ovarian function suppression may gain 10 to 15 percent improvement in freedom from distant recurrence at eight years, according to a new clinical trial analysis reported at the annual meeting of the American […]

View full entry

Tags: Breast Cancer, Dana Farber Cancer Center, Harvard, News, premenopausal breast cancer treatment


July 6, 2018

Engineering the Common Cold Virus Appears to be Promising Treatment Approach for Some Brain Tumors

By

A “smart bomb” oncolytic adenovirus appears to induce dramatic responses with long-term survival in recurrent high-grade gliomas, according to the early results of a study published in The Journal of Clinical Oncology. Glioblastoma is the most common and aggressive form of primary brain cancer in adults. With standard therapy — surgery followed by chemoradiation and […]

View full entry

Tags: Brain Cancer, News


July 3, 2018

Xalkori® Receives FDA Breakthrough Therapy Designation for Anaplastic Large Cell Lymphoma

By

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Xalkori® (crizotinib) for the treatment of patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) that is anaplastic lymphoma kinase (ALK)-positive. The FDA’s Breakthrough Therapy designation is intended to expedite the development and review of a medicine if it is intended […]

View full entry

Tags: News, Non-Hodgkin's Lymphoma


June 25, 2018

FDA Approves Venetoclax for Chronic and Small Lymphocytic Leukemia/Lymphoma With or Without 17 p Deletion,

By

The Food and Drug Administration granted regular approval to Venclexta (venetoclax) for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy. Approval was based on a multicenter, open-label clinical trial of venclexta with rituximab (VEN+R) versus bendamustine with rituximab (B+R) […]

View full entry

Tags: Chronic Lymphocytic Leukemia, Leukemia, News


June 25, 2018

Precision Cancer Medicine PARP Inhibitor Promising Treatment for Small Cell Lung Cancer

By

The results of a recent study published in The Journal of Clinical Oncology suggest the first new therapeutic option for Small Cell Lung Cancer (SCLC) in many years.  The study evaluated the addition of a novel precision cancer medicine called a PARP inhibitor to standard chemotherapy improved overall response rates and delayed cancer progression in patients […]

View full entry

Tags: Lung Cancer, Lung Cancer - Small Cell, News, PARP Inhibitor Treatment, Precision Cancer Medicine, small cell lung cancer


June 22, 2018

Keytruda Trail Results Suggest Change in Management of Squamous Non-Small Cell Lung Cancer

By

An interim analysis of the phase III KEYNOTE-407 trial evaluated combined chemotherapy and immunotherapy showed a more than four-month longer median overall survival for metastatic squamous non–small-cell lung cancer (NSCLC) patients who received keytruda (pembrolizumab) plus traditional chemotherapy compared with those who received placebo plus chemotherapy. About Lung Cancer Lung cancer remains the leading cause […]

View full entry

Tags: immunotherapy, keytruda, Lung Cancer, News, nsclc, pembrolizumab, Precision Cancer Medicine, squamous non–small-cell lung cancer


June 21, 2018

U.S. FDA Agrees to Review Talazoparib for Advanced and Triple Negative Breast Cancer for Treatment of Patients with an Inherited BRCA Mutation

By

The U.S. Food and Drug Administration accepted for filing and granted Priority Review designation for Pfizer’s New Drug Application for talazoparib. The submission is based on results from the EMBRACA trial, which compared talazoparib to chemotherapy in patients with inherited BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer. About Talazoparib Talazoparib is an investigational anti-cancer […]

View full entry

Tags: Breast Cancer, News


June 19, 2018

mFOLFIRINOX Found Superior to Gemzar for Treatment Surgically Resected Pancreatic Cancer

By

The results of a recently presented clinical study at the American Society of Clinical Oncology meetings last week suggest that more aggressive chemotherapy treatment improves outcomes compared to single agent Gemzar (gemcitabine) chemotherapy which has been a standard treatment for over a decade. About Pancreatic Cancer Pancreatic cancer is one of the deadliest forms of […]

View full entry

Tags: Chemotherapy, gemzar, mFOLFIRINOX, News, Pancreatic Cancer, treatment